{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:09:22Z","timestamp":1787634562031,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1037,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1111\/bjd.12010","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T10:41:06Z","timestamp":1345632066000},"page":"987-994","source":"Crossref","is-referenced-by-count":98,"title":["Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities"],"prefix":"10.1093","volume":"167","author":[{"given":"R.","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Newton-Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fearfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"10.1111\/bjd.12010-BIB1|cit1","unstructured":"International Agency for Research on Cancer Globocan. Country Fast Statistics IARC http:\/\/globocan.iarc.fr\/"},{"key":"10.1111\/bjd.12010-BIB2|cit2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival bench marks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB3|cit3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised U.K. guidelines for management of cutaneous melanoma","volume":"163","author":"Marsden","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12010-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB5|cit5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB6|cit6","unstructured":"European Medicines Agency Yervoy http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002213\/WC500106522.pdf"},{"key":"10.1111\/bjd.12010-BIB7|cit7","unstructured":"European Medicines Agency European Medicines Agency recommends approval of first-in-class treatment for metastatic or unresectable melanoma http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2011\/12\/WC500119378.pdf"},{"key":"10.1111\/bjd.12010-BIB8|cit8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB10|cit10","unstructured":"Roche Products Limited Zelboraf 240\u2003mg film-coated tablets. Summary of Product Characteristics 2012 http:\/\/www.medicines.org.uk\/EMC\/medicine\/26056\/SPC\/Zelboraf+240+mg+Film-coated+Tablets\/"},{"key":"10.1111\/bjd.12010-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB12|cit12","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumours","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB13|cit13","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12010-BIB14|cit14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB15|cit15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1111\/bjd.12010-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/bjd.12010-BIB20|cit20","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1111\/bjd.12010-BIB21|cit21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.0022-202X.2004.23402.x","article-title":"BRAF kinase gene V599E mutation in growing melanocytic lesions","volume":"123","author":"Loewe","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12010-BIB22|cit22","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"Ugurel","year":"2007","journal-title":"PLoS One"},{"key":"10.1111\/bjd.12010-BIB23|cit23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB24|cit24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1111\/bjd.12010-BIB25|cit25","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/jco.2012.30.15_suppl.8517","article-title":"An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma","volume":"30","author":"Larkin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12010-BIB26|cit26","unstructured":"Flaherty KT Building on BRAF inhibition in melanoma and extending to other cancers the ASCO Annual Meeting"},{"key":"10.1111\/bjd.12010-BIB27|cit27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB28|cit28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Ro\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12010-BIB29|cit29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2009-0055","article-title":"Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K","volume":"14","author":"Thatcher","year":"2009","journal-title":"Oncologist"},{"key":"10.1111\/bjd.12010-BIB30|cit30","first-page":"891","article-title":"Cutaneous drug eruptions induced by sorafenib: a case series","volume":"7","author":"Maddox","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.12010-BIB31|cit31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-4632.2010.04822.x","article-title":"Sorafenib-induced premalignant and malignant skin lesions","volume":"50","author":"Williams","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.12010-BIB32|cit32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2008.10.043","article-title":"The histologic spectrum of epithelial neoplasms induced by sorafenib","volume":"61","author":"Kwon","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12010-BIB33|cit33","first-page":"161","article-title":"Hypersensitivity reactions to chemotherapy drugs","volume":"15","author":"D\u00e1vila Gonz\u00e1lez","year":"2000","journal-title":"Alergol Immunol Clin"},{"key":"10.1111\/bjd.12010-BIB34|cit34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB35|cit35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1111\/bjd.12010-BIB36|cit36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1111\/bjd.12010-BIB37|cit37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12010-BIB38|cit38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12010-BIB39|cit39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.12010-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12010","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12010\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:02:38Z","timestamp":1676365358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/5\/987\/6614134"}},"subtitle":["Cutaneous adverse events with vemurafenib: practical advice"],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12010","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,29]]}}}